Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

This Tuesday, the Health Ministry will begin training medical teams ahead of a historic campaign to protect all Israeli ...

Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not ...

Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the peak of the season, a number they hope will increase as more women are ...

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

HHS Secretary Robert F. Kennedy Jr. last month quietly endorsed recommendations from his handpicked vaccine advisors that ...

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.